|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Casimiro MC, Velasco-Velázquez M,
Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function
in cancer and the CDK inhibitor landscape: Past and present. Expert
Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
4
|
Jang HD, Noh JY, Shin JH, Lin JJ and Lee
SY: PTEN regulation by the Akt/GSK-3β axis during RANKL signaling.
Bone. 55:126–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang G, Jiang X, Pu H, Zhang W, An C, Hu
X, Liou AK, Leak RK, Gao Y and Chen J: Scriptaid, a novel histone
deacetylase inhibitor, protects against traumatic brain injury via
modulation of PTEN and AKT pathway: Scriptaid protects against TBI
via AKT. Neurotherapeutics. 10:124–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan L, Lu J, Wang X, Han L, Zhang Y, Han S
and Huang B: Histone deacetylase inhibitor trichostatin A
potentiates doxorubicin-induced apoptosis by up-regulating PTEN
expression. Cancer. 109:1676–1688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peserico A and Simone C: Physical and
functional HAT/HDAC interplay regulates protein acetylation
balance. J Biomed Biotechnol. 2011:3718322011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ,
Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, et al: Aberrant
regulation of HDAC2 mediates proliferation of hepatocellular
carcinoma cells by deregulating expression of G1/S cell cycle
proteins. PLoS One. 6:e281032011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poyet C, Jentsch B, Hermanns T,
Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild
PJ and Kristiansen G: Expression of histone deacetylases 1, 2 and 3
in urothelial bladder cancer. BMC Clin Pathol. 14:102014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giaginis C, Damaskos C, Koutsounas I,
Zizi-Serbetzoglou A, Tsoukalas N, Patsouris E, Kouraklis G and
Theocharis S: Histone deacetylase (HDAC)-1, −2, −4 and −6
expression in human pancreatic adenocarcinoma: Associations with
clinicopathological parameters, tumor proliferative capacity and
patients' survival. BMC Gastroenterol. 15:1482015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ,
Kim HS, Nam B, Shin WC, Lee EK, Lee K, et al: HDAC2 provides a
critical support to malignant progression of hepatocellular
carcinoma through feedback control of mTORC1 and AKT. Cancer Res.
74:1728–1738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Zhao B, Huang C, Meng XM, Bian EB
and Li J: Melittin restores PTEN expression by down-regulating
HDAC2 in human hepatocelluar carcinoma HepG2 cells. PLoS One.
9:e955202014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krishnan AV and Feldman D: Mechanisms of
the anti-cancer and anti-inflammatory actions of vitamin D. Annu
Rev Pharmacol Toxicol. 51:311–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feldman D, Krishnan AV, Swami S,
Giovannucci E and Feldman BJ: The role of vitamin D in reducing
cancer risk and progression. Nat Rev Cancer. 14:342–357. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toropainen S, Väisänen S, Heikkinen S and
Carlberg C: The down-regulation of the human MYC gene by the
nuclear hormone 1α,25-dihydroxyvitamin D3 is associated
with cycling of corepressors and histone deacetylases. J Mol Biol.
400:284–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang J, Yang G, Huang Y, Kong W and Zhang
S: 1,25(OH)2D3 inhibits the progression of
hepatocellular carcinoma via downregulating HDAC2 and upregulating
P21(WAFI/CIP1). Mol Med Rep. 13:1373–1380. 2016.PubMed/NCBI
|
|
17
|
Nibbelink KA, Tishkoff DX, Hershey SD,
Rahman A and Simpson RU: 1,25(OH)2-vitamin D3
actions on cell proliferation, size, gene expression, and receptor
localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol
Biol. 103:533–537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jozilan HN, Horvath P, Kosa JP, Lakatos P,
Nemeth D, Wölfling J, Kovacs D, Bodnar B, Matyus P, Horvath E, et
al: P0321: Increased anti-tumor effect of vitamin D after CYP24A1
inhibition on HCC cell lines. J Hepatol. 62:(Suppl 2). S4292015.
View Article : Google Scholar
|
|
19
|
Fingas CD, Altinbas A, Schlattjan M,
Beilfuss A, Sowa JP, Sydor S, Bechmann LP, Ertle J, Akkiz H, Herzer
K, et al: Expression of apoptosis- and vitamin D pathway-related
genes in hepatocellular carcinoma. Digestion. 87:176–181. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruijtenberg S and van den Heuvel S:
Coordinating cell proliferation and differentiation: Antagonism
between cell cycle regulators and cell type-specific gene
expression. Cell Cycle. 15:196–212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ,
Shen Q, Kim MG, Chang YG, Kim SJ, Park WS, et al: Targeted
inactivation of HDAC2 restores p16INK4a activity and
exerts antitumor effects on human gastric cancer. Mol Cancer Res.
11:62–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee YH, Seo D, Choi KJ, Andersen JB, Won
MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, et
al: Antitumor effects in hepatocarcinoma of isoform-selective
inhibition of HDAC2. Cancer Res. 74:4752–4761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang WJ, Lin CW, Lee CY, Chi LL, Chao YC,
Wang HN, Chiou BL, Chen TJ, Huang CY and Chen CN: NBM-HD-3, a novel
histone deacetylase inhibitor with anticancer activity through
modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol.
136:156–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
